Traders should monitor upcoming clinical data in H1 2026 for AlloNK in refractory RA, which could serve as a key catalyst. Despite growing losses and zero revenue, the cash runway provides near-term stability, reducing immediate dilution risk.
ARTV drugs
ARTV drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 11 $7.13entry
- T+1 · 8mo ago −5.33%α −3.85% · $6.75
- T+5 · 8mo ago −18.65%α −16.47% · $5.80
- T+20 · 7mo ago −4.63%α −5.15% · $6.80
- T+60 · 6mo ago −2.24%α −13.77% · $6.97
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Artiva Biotherapeutics reported its full-year 2025 financial results, highlighting a net loss of $83.9 million, increased R&D spending, and a strong cash position of $108.0 million that funds operations into Q2 2027. The company emphasized clinical progress with AlloNK in refractory rheumatoid arthritis, including FDA Fast Track designation and upcoming data readouts in H1 2026, but reported zero revenue for the year.
Key Financial Metrics
Key Facts
- Net loss was $83.9 million in 2025 vs. $65.4 million in 2024
- Cash, cash equivalents, and investments totaled $108.0 million as of December 31, 2025, down from $185.4 million in 2024
- Cash runway extends into Q2 2027
- License and development support revenue was $0 in 2025 vs. $0.3 million in 2024
- R&D expenses increased to $69.5 million from $50.3 million in 2024
- Initial clinical response data in refractory RA expected in first half of 2026
- FDA interaction planned in first half of 2026 to discuss pivotal trial design
Financial Impact
Increased R&D spend by $19.2 million YoY; cash burn of ~$77.4 million (net loss plus non-cash items); revenue declined to zero
Risk Factors
- High cash burn with no current revenue stream
- Clinical data in H1 2026 may not meet expectations, risking valuation decline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253311 |
Track record
33 reports on ARTV
11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers